Medicina (Dec 2021)

Comparison of Spinal Cord Stimulation vs. Dorsal Root Ganglion Stimulation vs. Association of Both in Patients with Refractory Chronic Back and/or Lower Limb Neuropathic Pain: An International, Prospective, Randomized, Double-Blinded, Crossover Trial (BOOST-DRG Study)

  • Philippe Rigoard,
  • Manuel Roulaud,
  • Lisa Goudman,
  • Nihel Adjali,
  • Amine Ounajim,
  • Jimmy Voirin,
  • Christophe Perruchoud,
  • Bénédicte Bouche,
  • Philippe Page,
  • Rémy Guillevin,
  • Mathieu Naudin,
  • Martin Simoneau,
  • Bertille Lorgeoux,
  • Sandrine Baron,
  • Kevin Nivole,
  • Mathilde Many,
  • Iona Maitre,
  • Raphaël Rigoard,
  • Romain David,
  • Maarten Moens,
  • Maxime Billot

DOI
https://doi.org/10.3390/medicina58010007
Journal volume & issue
Vol. 58, no. 1
p. 7

Abstract

Read online

While spinal cord stimulation (SCS) is a well-established therapy to address refractory persistent spinal pain syndrome after spinal surgery (PSPS-T2), its lack of spatial selectivity and reported discomfort due to positional effects can be considered as significant limitations. As alternatives, new waveforms, such as burst stimulation and different spatial neural targets, such as dorsal root ganglion stimulation (DRGS), have shown promising results. Comparisons between DRGS and standard SCS, or their combination, have never been studied on the same patients. “BOOST DRG” is the first prospective, randomized, double-blinded, crossover study to compare SCS vs. DRGS vs. SCS+DRGS. Sixty-six PSPS-T2 patients will be recruited internationally in three centers. Before crossing over, patients will receive each stimulation modality for 1 month, using tonic conventional stimulation. After 3 months, stimulation will consist in switching to burst for 1 month, and patients will choose which modality/waveform they receive and will then be reassessed at 6 and 12 months. In addition to our primary outcome based on pain rating, this study is designed to assess quality of life, functional disability, psychological distress, pain surface coverage, global impression of change, medication quantification, adverse events, brain functional imaging and electroencephalography, with the objective being to provide a multidimensional insight based on composite pain assessment.

Keywords